Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces that the Company will issue 35,925 ordinary shares of 1 penny each (“Option Shares”) in settlement of options that have been exercised. The options were exercised at a price of US $0.20 per ordinary share for total consideration of US $7,185.
Admission to trading on AIM (“Admission”) of the Option Shares, which will rank pari passu with the existing Ordinary Shares, will be applied for, and it is expected that Admission will become effective and dealings in the new Ordinary Shares will commence on 29 December 2015.
Total Voting Rights
Following Admission, the total issued share capital of the Company will be 108,601,496 Ordinary Shares with one voting right each. The Company does not hold any shares in treasury.
Accordingly, the total voting rights in the Company will be 108,601,496. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure and Transparency Rules of the UK Financial Conduct Authority.
Motif Bio plc
Graham Lumsden, Chief Executive Officer
Zeus Capital Limited (Nominated Advisor and Broker)
Phil Walker / Dan Bate
+44 (0) 20 3829 5000
Northland Capital Partners (Broker)
Patrick Claridge / David Hignell
John Howes / Mark Treharne (Broking)
+44 (0) 207 382 1100
MC Services AG (Trade PR)
+49 (0) 89 210 2280
+44 (0) 207 148 5998
Plumtree Capital Limited (Financial Advisor)
+44 (0) 207 183 2493
Yellow Jersey PR (Financial PR)
+44 (0) 7747 788 221
Notes to Editors
Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria. For additional information about Motif please visit www.motifbio.com.